Understanding therapeutic equivalence in epilepsy

Raman Sankar, Tracy A. Glauser, Jacquelyn Bainbridge, Selim R. Benbadis, Raymond E. Faught, Frank Gilliam, Michael Gruenthal, Laura L. Hershkowitz, Gregory L. Holmes, Aatif M. Husain, David M Labiner, Georgia Montouris, Dean K. Naritoku, Barbara J. Olson, John M. Pellock, Patricia E. Penovich, R. Eugene Ramsay, Jong M. Rho, Karen C. Richards, William E. RosenfeldJeremy D. Slater, Michael C. Smith, Mark C. Spitz, John M. Stern, David G. Vossler, James W. Wheless

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The issues surrounding generic drug substitution in patients with epilepsy are complex. The substitution of one formulation of an antiepileptic drug (AED) for another is controversial. Well-reasoned and defensible cases can be made both for and against such substitution. Although regulatory agencies require that generic and proprietary drugs have similar pharmacokinetic bioequivalence data, their therapeutic efficacy may not necessarily be identical. The paroxysmal nature of epilepsy, the narrow therapeutic index of some AEDs, the need to individualize therapy to achieve seizure control, and the negative consequences of uncontrolled epilepsy distinguishes epilepsy from other clinical conditions. Epilepsy management with AEDs requires careful dose titration and consistent drug exposure at the optimal level for each patient, which can be altered if a different formulation of the AED is substituted. Unexpected variability in plasma concentrations could occur when a patient who has been receiving one formulation of an AED (generic or brand) receives an alternate formulation. Thus, no substitutions should be made for people with epilepsy without the knowledge and approval of the prescribing physician. Patients should be consulted about the substitution, with all risks and benefits carefully explained.

Original languageEnglish (US)
Pages (from-to)112-123
Number of pages12
JournalCNS Spectrums
Volume15
Issue number2
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Epilepsy
Drug Substitution
Anticonvulsants
Generic Drugs
Therapeutics
Therapeutic Equivalency
Seizures
Pharmacokinetics
Physicians
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Sankar, R., Glauser, T. A., Bainbridge, J., Benbadis, S. R., Faught, R. E., Gilliam, F., ... Wheless, J. W. (2010). Understanding therapeutic equivalence in epilepsy. CNS Spectrums, 15(2), 112-123.

Understanding therapeutic equivalence in epilepsy. / Sankar, Raman; Glauser, Tracy A.; Bainbridge, Jacquelyn; Benbadis, Selim R.; Faught, Raymond E.; Gilliam, Frank; Gruenthal, Michael; Hershkowitz, Laura L.; Holmes, Gregory L.; Husain, Aatif M.; Labiner, David M; Montouris, Georgia; Naritoku, Dean K.; Olson, Barbara J.; Pellock, John M.; Penovich, Patricia E.; Ramsay, R. Eugene; Rho, Jong M.; Richards, Karen C.; Rosenfeld, William E.; Slater, Jeremy D.; Smith, Michael C.; Spitz, Mark C.; Stern, John M.; Vossler, David G.; Wheless, James W.

In: CNS Spectrums, Vol. 15, No. 2, 02.2010, p. 112-123.

Research output: Contribution to journalArticle

Sankar, R, Glauser, TA, Bainbridge, J, Benbadis, SR, Faught, RE, Gilliam, F, Gruenthal, M, Hershkowitz, LL, Holmes, GL, Husain, AM, Labiner, DM, Montouris, G, Naritoku, DK, Olson, BJ, Pellock, JM, Penovich, PE, Ramsay, RE, Rho, JM, Richards, KC, Rosenfeld, WE, Slater, JD, Smith, MC, Spitz, MC, Stern, JM, Vossler, DG & Wheless, JW 2010, 'Understanding therapeutic equivalence in epilepsy', CNS Spectrums, vol. 15, no. 2, pp. 112-123.
Sankar R, Glauser TA, Bainbridge J, Benbadis SR, Faught RE, Gilliam F et al. Understanding therapeutic equivalence in epilepsy. CNS Spectrums. 2010 Feb;15(2):112-123.
Sankar, Raman ; Glauser, Tracy A. ; Bainbridge, Jacquelyn ; Benbadis, Selim R. ; Faught, Raymond E. ; Gilliam, Frank ; Gruenthal, Michael ; Hershkowitz, Laura L. ; Holmes, Gregory L. ; Husain, Aatif M. ; Labiner, David M ; Montouris, Georgia ; Naritoku, Dean K. ; Olson, Barbara J. ; Pellock, John M. ; Penovich, Patricia E. ; Ramsay, R. Eugene ; Rho, Jong M. ; Richards, Karen C. ; Rosenfeld, William E. ; Slater, Jeremy D. ; Smith, Michael C. ; Spitz, Mark C. ; Stern, John M. ; Vossler, David G. ; Wheless, James W. / Understanding therapeutic equivalence in epilepsy. In: CNS Spectrums. 2010 ; Vol. 15, No. 2. pp. 112-123.
@article{c858e93290fe4064ade8acd38f0861fc,
title = "Understanding therapeutic equivalence in epilepsy",
abstract = "The issues surrounding generic drug substitution in patients with epilepsy are complex. The substitution of one formulation of an antiepileptic drug (AED) for another is controversial. Well-reasoned and defensible cases can be made both for and against such substitution. Although regulatory agencies require that generic and proprietary drugs have similar pharmacokinetic bioequivalence data, their therapeutic efficacy may not necessarily be identical. The paroxysmal nature of epilepsy, the narrow therapeutic index of some AEDs, the need to individualize therapy to achieve seizure control, and the negative consequences of uncontrolled epilepsy distinguishes epilepsy from other clinical conditions. Epilepsy management with AEDs requires careful dose titration and consistent drug exposure at the optimal level for each patient, which can be altered if a different formulation of the AED is substituted. Unexpected variability in plasma concentrations could occur when a patient who has been receiving one formulation of an AED (generic or brand) receives an alternate formulation. Thus, no substitutions should be made for people with epilepsy without the knowledge and approval of the prescribing physician. Patients should be consulted about the substitution, with all risks and benefits carefully explained.",
author = "Raman Sankar and Glauser, {Tracy A.} and Jacquelyn Bainbridge and Benbadis, {Selim R.} and Faught, {Raymond E.} and Frank Gilliam and Michael Gruenthal and Hershkowitz, {Laura L.} and Holmes, {Gregory L.} and Husain, {Aatif M.} and Labiner, {David M} and Georgia Montouris and Naritoku, {Dean K.} and Olson, {Barbara J.} and Pellock, {John M.} and Penovich, {Patricia E.} and Ramsay, {R. Eugene} and Rho, {Jong M.} and Richards, {Karen C.} and Rosenfeld, {William E.} and Slater, {Jeremy D.} and Smith, {Michael C.} and Spitz, {Mark C.} and Stern, {John M.} and Vossler, {David G.} and Wheless, {James W.}",
year = "2010",
month = "2",
language = "English (US)",
volume = "15",
pages = "112--123",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "2",

}

TY - JOUR

T1 - Understanding therapeutic equivalence in epilepsy

AU - Sankar, Raman

AU - Glauser, Tracy A.

AU - Bainbridge, Jacquelyn

AU - Benbadis, Selim R.

AU - Faught, Raymond E.

AU - Gilliam, Frank

AU - Gruenthal, Michael

AU - Hershkowitz, Laura L.

AU - Holmes, Gregory L.

AU - Husain, Aatif M.

AU - Labiner, David M

AU - Montouris, Georgia

AU - Naritoku, Dean K.

AU - Olson, Barbara J.

AU - Pellock, John M.

AU - Penovich, Patricia E.

AU - Ramsay, R. Eugene

AU - Rho, Jong M.

AU - Richards, Karen C.

AU - Rosenfeld, William E.

AU - Slater, Jeremy D.

AU - Smith, Michael C.

AU - Spitz, Mark C.

AU - Stern, John M.

AU - Vossler, David G.

AU - Wheless, James W.

PY - 2010/2

Y1 - 2010/2

N2 - The issues surrounding generic drug substitution in patients with epilepsy are complex. The substitution of one formulation of an antiepileptic drug (AED) for another is controversial. Well-reasoned and defensible cases can be made both for and against such substitution. Although regulatory agencies require that generic and proprietary drugs have similar pharmacokinetic bioequivalence data, their therapeutic efficacy may not necessarily be identical. The paroxysmal nature of epilepsy, the narrow therapeutic index of some AEDs, the need to individualize therapy to achieve seizure control, and the negative consequences of uncontrolled epilepsy distinguishes epilepsy from other clinical conditions. Epilepsy management with AEDs requires careful dose titration and consistent drug exposure at the optimal level for each patient, which can be altered if a different formulation of the AED is substituted. Unexpected variability in plasma concentrations could occur when a patient who has been receiving one formulation of an AED (generic or brand) receives an alternate formulation. Thus, no substitutions should be made for people with epilepsy without the knowledge and approval of the prescribing physician. Patients should be consulted about the substitution, with all risks and benefits carefully explained.

AB - The issues surrounding generic drug substitution in patients with epilepsy are complex. The substitution of one formulation of an antiepileptic drug (AED) for another is controversial. Well-reasoned and defensible cases can be made both for and against such substitution. Although regulatory agencies require that generic and proprietary drugs have similar pharmacokinetic bioequivalence data, their therapeutic efficacy may not necessarily be identical. The paroxysmal nature of epilepsy, the narrow therapeutic index of some AEDs, the need to individualize therapy to achieve seizure control, and the negative consequences of uncontrolled epilepsy distinguishes epilepsy from other clinical conditions. Epilepsy management with AEDs requires careful dose titration and consistent drug exposure at the optimal level for each patient, which can be altered if a different formulation of the AED is substituted. Unexpected variability in plasma concentrations could occur when a patient who has been receiving one formulation of an AED (generic or brand) receives an alternate formulation. Thus, no substitutions should be made for people with epilepsy without the knowledge and approval of the prescribing physician. Patients should be consulted about the substitution, with all risks and benefits carefully explained.

UR - http://www.scopus.com/inward/record.url?scp=77949284499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949284499&partnerID=8YFLogxK

M3 - Article

C2 - 20414156

AN - SCOPUS:77949284499

VL - 15

SP - 112

EP - 123

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 2

ER -